EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Water-Free Cyclosporine 0.1% in Dry Eye Disease: Formulation Rationale, Clinical Evidence, and Unresolved Questions

Eleftherios Chatzimichail, Mohamed Elalfy, Theo Empeslidis, Georgios D Panos iD, Zisis Gatzioufas

Drug Design, Development and Therapy · 2026-08 · Volume 20 · 1-9

DOI: 10.2147/dddt.s620553 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026-08. Verfasst von Eleftherios Chatzimichail und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Cyclosporine, Dry Eye Syndromes, Immunosuppressive Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineDry Eye SyndromesImmunosuppressive AgentsHumansOphthalmic SolutionsAnimalsWater

Stichwörter der Autor:innen

CyclASolcyclosporinedry eye diseaseocular surface diseaseperfluorobutylpentane/F4H5semifluorinated alkaneswater-free cyclosporine

Substanzen

CyclosporineOphthalmic SolutionsWaterImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, University Hospital of Basel, Basel, Switzerland.
  • Corneoplastic Unit, Queen Victoria Hospital, East Grinstead, UK.
  • Research Institute of Ophthalmology, Giza, Egypt.
  • Maidstone and Tunbridge Wells Hospital NHS Trust, Kent, UK.
  • Vantage Biosciences, London, UK.
  • First Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

ORCID-Profile: Georgios D Panos

Zitieren

APA

Chatzimichail, E., Elalfy, M., Empeslidis, T., Panos, G. D., & Gatzioufas, Z. (2026). Water-Free Cyclosporine 0.1% in Dry Eye Disease: Formulation Rationale, Clinical Evidence, and Unresolved Questions. Drug Design, Development and Therapy, Volume 20, 1-9. https://doi.org/10.2147/dddt.s620553

Vancouver

Chatzimichail E, Elalfy M, Empeslidis T, Panos GD, Gatzioufas Z. Water-Free Cyclosporine 0.1% in Dry Eye Disease: Formulation Rationale, Clinical Evidence, and Unresolved Questions. Drug Design, Development and Therapy. 2026;Volume 20:1-9. doi:10.2147/dddt.s620553

BibTeX
@article{Chatzimichail2026,
  author = {Chatzimichail, Eleftherios and Elalfy, Mohamed and Empeslidis, Theo and Panos, Georgios D and Gatzioufas, Zisis},
  title = {Water-Free Cyclosporine 0.1% in Dry Eye Disease: Formulation Rationale, Clinical Evidence, and Unresolved Questions},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--9},
  doi = {10.2147/dddt.s620553}
}
Kostenlos starten →